Multifunctional Modulators of Drug Resistance
作者： John R. Murren , Germana Rappa , Yung-Chi Cheng
DOI: 10.1007/978-1-4613-1267-3_16
关键词:
摘要: A variety of specific biochemical mechanisms have been identified that allow tumors to escape the cytotoxic effect chemotherapy. Resistance may be induced one particular class cytotoxins, such as resistance methotrexate associated with a mutational change in target enzyme dihydrofolate reductase. also develop cross section structurally unrelated classes chemotherapy, multidrug (MDR) phenotype laboratories Tsuruo [1], Biedler [2], and Ling [3].
springer.com
sci-hub.st 参考文章(159)
G. Buccheri, D. Ferrigno, A randomised trial of MACC chemotherapy with or without lonidamine in advanced non-small cell lung cancer European Journal of Cancer. ,vol. 30, pp. 1424- 1431 ,(1993) , 10.1016/0959-8049(94)00286-E
Karl Drlica, Robert J. Franco, Inhibitors of DNA topoisomerases Biochemistry. ,vol. 27, pp. 2253- 2259 ,(1988) , 10.1021/BI00407A001
G Citro, C Cucco, A Verdina, G Zupi, Reversal of adriamycin resistance by lonidamine in a human breast cancer cell line. British Journal of Cancer. ,vol. 64, pp. 534- 536 ,(1991) , 10.1038/BJC.1991.345
David J. Stewart, Libni Eapen, Andre Girard, Shailendra Verma, Paul Genest, William K. Evans, Phase II study of lonidamine plus radiotherapy in the treatment of brain metastases. Journal of Neuro-oncology. ,vol. 15, pp. 19- 22 ,(1993) , 10.1007/BF01050258
Caroline S Tanwell, Andreas Gescher, Tracey D. Bradshaw, George R. Pettit, The role of protein kinase C isoenzymes in the growth inhibition caused by bryostatin 1 in human A549 lung and MCF-7 breast carcinoma cells. International Journal of Cancer. ,vol. 56, pp. 585- 592 ,(1994) , 10.1002/IJC.2910560420
Yuichiro Takeda, Kazuto Nishio, Yoshikazu Sugimoto, Kazuo Kasahara, Sachiyo Kubo, Yasuhiro Fujiwara, Nagahiro Saijo, Hisanobu Niitani, Establishment of a human leukemia subline resistant to the growth-inhibitory effect of 12-O-tetradecanoylphorbol 13-acetate (TPA) and showing non-P-glycoprotein-mediated multi-drug resistance. International Journal of Cancer. ,vol. 48, pp. 931- 937 ,(1991) , 10.1002/IJC.2910480622
P Pronzato, D Amoroso, G Bertelli, PF Conte, MP Cusimano, GB Ciottoli, M Gulisano, R Lionetto, R Rosso, Phase II study of lonidamine in metastatic breast cancer. British Journal of Cancer. ,vol. 59, pp. 251- 253 ,(1989) , 10.1038/BJC.1989.51
A. Gadducci, I. Brunetti, M.P. Muttini, A. Fanucchi, F. Dargenio, P.G. Giannessi, P.F. Conte, Epidoxorubicin and lonidamine in refractory or recurrent epithelial ovarian cancer European Journal of Cancer. ,vol. 30, pp. 1432- 1435 ,(1994) , 10.1016/0959-8049(94)00231-S
Cinzia Lanzi, Romolo Achille Gambetta, Paola Perego, Patrizia Banfi, Aimarita Franzi, Lorena Guazzoni, Franco Zunino, Protein kinase C activation by anthracyclines in Swiss 3T3 cells International Journal of Cancer. ,vol. 47, pp. 136- 142 ,(1991) , 10.1002/IJC.2910470124
SHUNICHI SUGAWARA, NOBUKO KUMANO, YASUO SAIJO, SHUJI SUZUKI, YUKA NUMATA, GEORGE SATO, MASAKICHI MOTOMIYA, Protein Kinase C Activity in Human Leukemia Cell Lines with Reference to Sensitivity to Antineoplastic Agents Tohoku Journal of Experimental Medicine. ,vol. 168, pp. 393- 396 ,(1992) , 10.1620/TJEM.168.393